Despite lackluster sales of Eylea’s high-dose formulation and Sanofi-partnered Dupixent, Regeneron beat Q4 forecasts overall ...

Q4 2024 Management View CEO Leonard Schleifer highlighted 10% revenue growth in Q4 2024, attributed to strong performance from Dupixent, Libtayo, and EYLEA HD. He emphasized the acceleration in EYLEA ...

Marion McCourt; Executive Vice President - Commercial; Regeneron Pharmaceuticals Inc. Christopher Fenimore; Chief Financial Officer, Senior Vice President - Finance; Regeneron Pha ...

Moments after Regeneron CEO Len Schleifer scolded analysts for asking too many questions about the disappointing sales of eye ...

Regeneron reported Q4 2024 earnings today and declared its first-ever dividend of $0.88 per quarter. Click here to know what ...

Biotech company Regeneron (NASDAQ:REGN) reported Q4 CY2024 results , with sales up 10.3% year on year to $3.79 billion. Its ...

Reports Q4 revenue $3.79B, consensus $3.75B. “Regeneron’s (REGN) financial and commercial strength allows for continued investment in our ...

In an interview on CNBC’s Mad Money, Len Schleifer said Regeneron (REGN) currently has 40 drugs in development representing billions in potential sales. “We know how to make and develop drugs ...

Regeneron Pharmaceuticals Inc (NASDAQ:REGN) reported fourth-quarter adjusted EPS of $12.07, up 2% year-over-year, beating the ...

“I’d be happier to talk about the pipeline,” Schleifer said. Earlier on Monday, Regeneron shared preliminary results from the fourth quarter that showed Eylea HD generated just $305 million ...

Regeneron (NASDAQ: REGN )'s flagship eye drug franchise, consisting of EYLEA HD and EYLEA, saw U.S. net sales increase 2% to ...

Regeneron collaborates with Truveta and ... that make a meaningful impact on patients’ lives,” said Leonard S. Schleifer, M.D., Ph.D., Board co-Chair, President and Chief Executive Officer ...